跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

73529

Supelco

氯倍他索

pharmaceutical impurity standard, ≥95.0% (HPLC)

别名:

Clobetasol propionate impurity G (PhEur), (11β,16β)-21-Chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C22H28ClFO4
CAS号:
25122-41-2
分子量:
410.91
EC號碼:
246-633-8
MDL號碼:
MFCD03695616
分類程式碼代碼:
41116107
PubChem物質ID:
329763802

等級

analytical standard

化驗

≥95.0% (HPLC)

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

雜質

≤10.0% related substances
≤5.0% solvents
≤5.0% water

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl

InChI

1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1

InChI 密鑰

FCSHDIVRCWTZOX-DVTGEIKXSA-N

應用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H360Df,H373,H413

危險分類

Aquatic Chronic 4 - Repr. 1B - STOT RE 2

標靶器官

Adrenal gland,Immune system

儲存類別代碼

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCBS7533V
BCBR2508V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

S Yawalkar et al.
Journal of the American Academy of Dermatology, 25(6 Pt 2), 1137-1144 (1991-12-01)
Both halobetasol propionate and clobetasol 17-propionate exerted very marked antiinflammatory, antiproliferative, and vasoconstrictive effects during evaluation in a range of dermatopharmacologic models. Halobetasol propionate was distinctly more potent than clobetasol 17-propionate in the ultraviolet-induced dermatitis inhibition assay in guinea pigs
Kai-Li Mao et al.
Colloids and surfaces. B, Biointerfaces, 160, 704-714 (2017-10-17)
A poor percutaneous penetration capability for most topical anti-inflammatory drugs is one of the main causes compromising their therapeutic effects on psoriatic skin. Even though curcumin has shown a remarkable efficacy in the treatment of psoriasis, its effective penetration through
Tina Bhutani et al.
The Journal of dermatological treatment, 23(1), 11-15 (2011-01-25)
Clobetasol 0.05% spray, a topical clobetasol propionate, is a non-greasy formulation that has shown increased clinical efficacy in a head-to-head comparison with foam formulation. Moreover, available data from randomized, controlled, double-blind trials suggests that clobetasol spray is, in fact, slightly
E A Olsen et al.
Journal of the American Academy of Dermatology, 15(2 Pt 1), 246-255 (1986-08-01)
Clobetasol-17-propionate, the most potent of currently available topical steroids as predicted by the vasoconstrictor assay, has just been approved in the United States. In psoriasis, it has proved significantly more effective than class II steroids and as or more effective
O Yélamos et al.
Journal of the European Academy of Dermatology and Venereology : JEADV, 35(1), 143-149 (2020-05-05)
Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. To compare the clinical
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门